Triptorelin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Triptorelin is a synthetic GnRH (gonadotropin-releasing hormone) super-agonist, FDA-approved as Trelstar (and marketed as Decapeptyl) for advanced prostate cancer, with established use in endometriosis and central precocious puberty. It is a legitimate, well-evidenced medication — but its therapeutic effect is the opposite of a libido or hormone-optimization peptide.
What does it do in my body?
A GnRH super-agonist works in two phases. Initially it stimulates the pituitary (a transient “flare” of LH/FSH and sex-hormone output). But with continuous, non-pulsatile exposure it downregulates and desensitizes pituitary GnRH receptors, shutting down gonadotropin release and driving sex-hormone production to castrate levels. That sustained suppression is the therapy in prostate cancer — it’s chemical castration, used deliberately to starve hormone-driven tumors. For contrast, the peptides people actually use to restore the HPG axis (enclomiphene, hCG, gonadorelin’s pulsatile use, kisspeptin) work the other direction — see the HPGA-restoration peptides.
How can it help me?
- Where the science stands: The most evidenced compound in this cluster — “strong” (30 studies, 19 human, up to Phase 4)
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Triptorelin is the OPPOSITE of a libido peptide. It was previously mis-tagged in an older directory pass under “sexual-function” — that tag has been removed, because triptorelin suppresses the HPG axis as its therapeutic effect. A consumer-facing recommendation cannot frame a chemical-castration drug under “libido & sexual performance”; even with red-flagging it would be misleading. Triptorelin is a powerful, legitimate prescription oncology/gynecology drug. It is not a self-directed performance or libido peptide, and using it as one would do the exact reverse of what a hormone-optimizing user wants. OHM does not recommend it for any consumer goal — it’s documented here so readers understand what it actually does. Any clinical use of triptorelin is a prescription decision made with a physician, and its known effects (initial hormone flare, then sustained suppression to castrate levels) are the therapy, not an incidental risk.
Regulatory status: FDA-approved prescription medication (Trelstar); prescription-only. Tier A / safety RED for catalog purposes / no consumer-goal mapping.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
Triptorelin has real, well-established clinical dosing — but only as a prescription drug for its approved indications (prostate cancer, endometriosis, central precocious puberty), administered and monitored by a physician. There is no self-directed “protocol” to give here, and giving one would misrepresent what this drug does: any off-label self-use aimed at libido or hormone optimization would drive the HPG axis in the wrong direction entirely.
What should I avoid combining — and what's synergistic?
Triptorelin doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for Triptorelin yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
A synthetic GnRH super-agonist, FDA-approved and heavily evidenced as a cancer/gynecology drug — whose therapeutic effect is the exact opposite of what a hormone-optimization or libido user would want. OHM documents it for what it is and does not recommend it for any consumer goal.
| Class | Synthetic GnRH (gonadotropin-releasing hormone) super-agonist, FDA-approved as Trelstar (also marketed as Decapeptyl) |
| Mechanism (one line) | Initially stimulates the pituitary, then desensitizes GnRH receptors under continuous exposure, shutting down gonadotropin release and driving sex hormones to castrate levels |
| Evidence base | The most evidenced compound in this cluster — “strong” (30 studies, 19 human, up to Phase 4) |
| Safety record | Well-characterized as a prescription oncology/gynecology drug; the therapeutic effect itself is HPG-axis suppression (chemical castration), not a side effect to manage |
| Regulatory status | FDA-approved prescription medication (Trelstar); prescription-only |
What it is
Triptorelin is a synthetic GnRH (gonadotropin-releasing hormone) super-agonist, FDA-approved as Trelstar (and marketed as Decapeptyl) for advanced prostate cancer, with established use in endometriosis and central precocious puberty. It is a legitimate, well-evidenced medication — but its therapeutic effect is the opposite of a libido or hormone-optimization peptide.
How it works
A GnRH super-agonist works in two phases. Initially it stimulates the pituitary (a transient “flare” of LH/FSH and sex-hormone output). But with continuous, non-pulsatile exposure it downregulates and desensitizes pituitary GnRH receptors, shutting down gonadotropin release and driving sex-hormone production to castrate levels. That sustained suppression is the therapy in prostate cancer — it’s chemical castration, used deliberately to starve hormone-driven tumors. For contrast, the peptides people actually use to restore the HPG axis (enclomiphene, hCG, gonadorelin’s pulsatile use, kisspeptin) work the other direction — see the HPGA-restoration peptides.
What the research shows
This is the most-evidenced compound in the whole cluster this article was migrated from. The underlying directory profile grades it “strong” (30 studies, 19 human, up to Phase 4), and the 0035 deep-research categorization pass grades it Tier A. Representative trials (all):
- Gravina A, et al. — ESMO Open 2025 (HOBOE, 10-yr update) n=1065 — triptorelin + letrozole improved disease-free survival in premenopausal HR+ early breast cancer. 39754976
- Li X, et al. — Adv Ther 2022 n=300 — triptorelin 3-month formulation non-inferior to 1-month for endometriosis. 35947347
- Yu X, et al. — Adv Ther 2024 n=66 — suppressed LH and slowed growth velocity in children with central precocious puberty. 39412628
The evidence is strong precisely for HPG-axis suppression — that’s the documented, intended effect.
Real-world protocol
Triptorelin has real, well-established clinical dosing — but only as a prescription drug for its approved indications (prostate cancer, endometriosis, central precocious puberty), administered and monitored by a physician. There is no self-directed “protocol” to give here, and giving one would misrepresent what this drug does: any off-label self-use aimed at libido or hormone optimization would drive the HPG axis in the wrong direction entirely.
Side effects & management
Triptorelin is the OPPOSITE of a libido peptide. It was previously mis-tagged in an older directory pass under “sexual-function” — that tag has been removed, because triptorelin suppresses the HPG axis as its therapeutic effect. A consumer-facing recommendation cannot frame a chemical-castration drug under “libido & sexual performance”; even with red-flagging it would be misleading. Triptorelin is a powerful, legitimate prescription oncology/gynecology drug. It is not a self-directed performance or libido peptide, and using it as one would do the exact reverse of what a hormone-optimizing user wants. OHM does not recommend it for any consumer goal — it’s documented here so readers understand what it actually does. Any clinical use of triptorelin is a prescription decision made with a physician, and its known effects (initial hormone flare, then sustained suppression to castrate levels) are the therapy, not an incidental risk.
Regulatory status
FDA-approved prescription medication (Trelstar); prescription-only. Tier A / safety RED for catalog purposes / no consumer-goal mapping.
Sources
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier A grading, RED safety flag, de-mapping from “sexual-function”
- PMIDs 39754976, 35947347, 39412628 — all
- Migrated from
frontier-investigational-peptides-cluster.md(Section 2)
Sources & references
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier A grading, RED safety flag, de-mapping from “sexual-function”
- PMIDs 39754976, 35947347, 39412628 — all
- Migrated from
frontier-investigational-peptides-cluster.md(Section 2)